In a recent interview former Food and Drug Administration (FDA) advisor turned whistleblower exposed how the FDA approves harmful drugs.
Dr. Aaron S. Kesselheim, MPH, began advising the Food and Drug Administration (FDA) in 2015, and then joined one of its advisory panels as a permanent member in 2019.
At that time, he was ready to use the skills he’d acquired in a successful medical career to help guide the agency he much respected.
But then, the FDA approved a drug called aducanumab (Aduhelm) to treat Alzheimer’s disease despite the advisory committee’s almost unanimous recommendation against that, which was based on a lack of evidence of success in treatment.
Kesselheim was concerned enough about the approval to resign from his important post. Since that resignation, Kesselheim has drawn public praise and written a New York Times opinion column on the topic.
It appears his and two other panel member’s departure was a factor in the decision&nbs...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
